Metabolism-based drug-drug interactions: What determines individual variability in cytochrome P450 induction?

Drug Metabolism and Disposition

Volumn 33, Issue 5, 2005, Pages 603-613

  Tang, Cuyue ^a   Lin, Jiunn H ^a,c,d   Lu, Anthony Y H ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c Amer Assoc Pharmaceutical S   (United States)

^d Amer Soc Pharmacol Exp T   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYMEPHENYTOIN; CHLORZOXAZONE; CYCLOSPORIN; CYTOCHROME P450; DEXAMETHASONE; ERYTHROMYCIN; ETHOXYRESORUFIN; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; MEPHENYTOIN; MIDAZOLAM; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PROPAFENONE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; STEROID; TRIAZOLAM; XENOBIOTIC AGENT;

DRUG CROSS REACTIVITY; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ENZYME INDUCTION; GENE; GENE CONTROL; GENETIC VARIABILITY; HUMAN; INDIVIDUALITY; PHENOTYPE; PRIORITY JOURNAL; REGULATOR GENE; REGULATORY MECHANISM; SHORT SURVEY;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; HUMANS; PHARMACEUTICAL PREPARATIONS; VARIATION (GENETICS);

EID: 17844385047     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.003236     Document Type: Short Survey

References (130)

1. Amakura Y, Tsutsumi T, Nakamura M, Kitagawa H, Fujino J, Sasaki K, Yoshida T, and Toyoda M (2002) Preliminary screening of the inhibitory effect of food extracts on activation of the aryl hydrocarbon receptor induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biol Pharm Bull 25:272-274.
2. Amakura Y, Tsutsumi T, Sasaki K, Yoshida T, and Maitani T (2003) Screening of the inhibitory effect of vegetable constituents on the aryl hydrocarbon receptor-mediated activity induced by 2,3,7,8-tetrachlorodibenzo-p- dioxin. Biol Pharm Bull 26:1754-1760.
3. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31:9-28.
4. Anttila S, Lei XD, Elovaara E, Karjalainen A, Sun W, Vainio H, and Hankinson O (2000) An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribable to polymorphisms in the AHR, ARNT, or CYP1A1 genes. Pharmacogenetics 10:741-751.
5. Ayrton A and Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497.
6. Backman JT, Olkkola KT, Ojala M, Laaksovirta H, and Neuvonen PJ (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37:253-257.
7. Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192-209.
8. Brigelius-Flohé R (2003) Vitamin E and drug metabolism. Biochem Biophys Res Commun 305:737-740.
9. Brinkmann U (2002) Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo. Novartis Found Symp 243:207-210.
10. Brogden RN and Fitton A (1994) Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:983-1009.
11. Burk O and Wojnowski L (2004) Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 369:105-124.
12. Cao H and Hegele RA (2000) Human aryl hydrocarbon receptor nuclear translocator gene (ARNT) D/N511 polymorphism. J Hum Genet 45:92-93.
13. Chang TK, Bandiera SM, and Chen J (2003) Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 31:7-10.
14. Cheng PY and Morgan ET (2001) Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2:165-183.
15. Chiba K, Kobayashi K, Manabe K. Tani M, Kamataki T, and Ishizaki T (1993) Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266:52-59.
16. Conney AH (2003) Induction of drug-metabolizing enzymes: a path to the discovery of multiple cytochrome P450. Annu Rev Pharmacol Toxicol 43:1-30.
17. Conney AH, Pantuck EJ, Hsiao KC, Garland WA, Anderson KE, Alvares AP, and Kappas A (1976) Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 20:633-642.
18. Coumoul X, Diry M, and Barouki R (2002) PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem Pharmacol 64:1513-1519.
19. Crowley JJ, Cusack BJ, Jue SG, Koup JR, Park BK, and Vestal RE (1988) Aging and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. J Pharmacol Exp Ther 245:513-523.
20. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, and Goldstein JA (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825-831.
21. de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, and Zhou HH (1995) Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58:405-411.
22. Diaz D, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel H, and Maurel P (1990) Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 99:737-747.
23. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, and Eichelbaum M (1999) Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics 9:551-559.
24. Dilger K, Hofmann U, and Klotz U (2000) Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 67:512-520.
25. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, and Henrich WL (2003) Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73:427-434.
26. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, and Fattinger K (2002) St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604.
27. Eichelbaum M and Burk O (2001) CYP3A genetics in drug metabolism. Nat Med 7:285-287.
28. Ernst E, Rand JI, Barnes J, and Stevinson C (1998) Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J Clin Pharmacol 54:589-594.
29. Farrell G (1999) Effects of disease on expression and regulation of P450s. Mol Asp Med 20:55-70.
30. Feng HJ, Huang SL, Wang W, and Zhou HH (1998) The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to CYP2C19*2 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 45:27-29.
31. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, and Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606.
32. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, and Klotz U (1998) Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol 45:247-255.
33. Fugh-Berman A (2000) Herb-drug interactions. Lancet 354:134-138.
34. Fukuen S, Fukuda T, Matsuda H, Sumida A, Yamamoto I, Inaba T, and Azuma J (2002) Identification of the novel splicing variants for the hPXR in human livers. Biochem Biophys Res Commun 298:433-438.
35. Goodwin B, Gauthier KC, Umetani M, Watson MA, Lochansky MI, Collins JL, Leitersdorf E, Mangelsdorf DJ, Kliewer SA, and Repa JJ (2003) Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci USA 100:223-228.
36. Goodwin B, Redinbo MR, and Kliewer SA (2002) Regulation of CYP3A gene transcription by the pregnane X receptor. Annu Rev Pharmacol Toxicol 42:1-23.
37. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, and Hall SD (2003) The effect of age, sex and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275-287.
38. Handschin C and Meyer UA (2003) Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 55:649-673.
39. Hankinson O (1995) The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35:307-340.
40. Harper PA, Wong JY, Lam MS, and Okey AB (2002) Polymorphisms in the human AH receptor. Chem-Biol Interact 141:161-187.
41. Hayashi S, Watanabe J, Nakachi K, Eguchi H, Gotoh O, and Kawajiri K (1994) Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis 15:801-806.
42. Hegele RA and Cao H (2001) Single nucleotide polymorphisms of RXRA encoding retinoid X receptor alpha. J Hum Genet 46:423-425.
43. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, Eichelbaum M, and Fromm MF (2001) The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11:293-298.
44. Hodek P, Trefil P, and Stiborova M (2002) Flavonoids - potent and versatile biologically active compounds interacting with cytochromes P450. Chem-Biol Interact 139:1-21.
45. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
46. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C. Brehm I, Brinkmann U, Eichelbaum M, Wojnowski L, et al. (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454-1459.
47. Ingelman-Sundberg M (2001) Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482:11-19.
48. Jamis-Dow CA, Katki AG, Collins JM, and Klecker RW (1997) Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 27:1015-1024.
49. Jeuken A, Keser BJ, Khan E, Brouwer A, Koeman J, and Denison MS (2003) Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables and fruits. J Agric Food Chem 51:5478-5487.
50. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, et al. (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27-39.
51. Kawana K, Ikuta T, Kobayashi Y, Gotoh O, Takeda K, and Kawajiri K (2003) Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR. Mol Pharmacol 63:524-531.
52. Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, Hamwi A, Fritzer-Szekeres M, Baumgartner C. Ongen HZ, et al. (2001) The predictive value of MDR1, CYP2C9 and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 1:204-210.
53. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, et al. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199.
54. Kliewer SA, Goodwin B, and Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687-702.
55. Kolars JC, Awmi WM, Merion RM, and Watkins PB (1991) First pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490.
56. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, and Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Investig 90:1871-1878.
57. Koyano S, Kurose K, Saito Y, Ozawa S, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Nakajima T, et al. (2004) Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 32:149-154.
58. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
59. Landes N, Birringer M, and Brigelius-Flohé R (2003a) Homologous metabolic and gene activating routes for vitamins E and K. Mol Asp Med 24:337-344.
60. Landes N, Pfluger P, Kluth D, Birringer M, Rühl R, Böl GF, Glatt H, and Brigelius-Flohé R (2003b) Vitamin E activates gene expression via the pregnane X receptor. Biochem Pharmacol 65:269-273.
61. Lin JH (2000) Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab 1:305-331.
62. Lin JH (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81.
63. Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
64. Lin JH and Lu AY (2001) Individual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41:535-567.
65. Lin P, Hu SW, and Chang TH (2003) Correlation between gene expression of aryl hydrocarbon receptor (AhR), hydrocarbon receptor nuclear translocator (Arnt), cytochromes P4501A1 (CYP1A1) and 1B1 (CYP1B1), and inducibility of CYP1A1 and CYP1B1 in human lymphocytes. Toxicol Sci 71:20-26.
66. Ma Q and Lu AYH (2003) Origins of individual variability in P451A induction. Chem Res Toxicol 16:249-269.
67. Manchester DK, Gordon SK, Golas CL, Roberts EA, and Okey AB (1987) Ah receptor in human placenta: stabilization by molybdate and characterization of binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 3-methylcholanthrene and benzo[a]pyrene. Cancer Res 47:4861-4868.
68. McCarver DG, Byun R, Hines RN, Hichme M, and Wegenek W (1998) A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 152:276-281.
69. Meyer UA and Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269-296.
70. Micka J, Milatovich A, Menon A, Grabowski GA, Puga A, and Neben DW (1997) Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics 7:95-101.
71. Moochhala SM (1991) Alteration of drug biotransformation by interferon and host defence mechanism. Ann Acad Med Singap 20:13-18.
72. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, and Kliewer SA (2000) St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500-7502.
73. Morgan ET (1993) Down-regulation of multiple cytochrome P450 gene products by inflammatory mediators in vivo. Independence from the hypothalamo-pituitary axis. Biochem Pharmacol 45:415-419.
74. Morgan ET (1997) Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29:1129-1188.
75. Morgan ET (2001) Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab Dispos 29:207-212.
76. Muntane-Relat J, Ourlin JC, Domergue J, and Maurel P (1995) Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2 and CYP3A4 in human hepatocytes in primary culture. Hepatology 22:1143-1153.
77. Murayama N, Soyama A, Saito Y, Nakajima, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kimura H, Goto Y, et al. (2004) Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 308:300-306.
78. Nagata K and Yamazoe Y (2002) Genetic polymorphism of human cytochrome P450 involved in drug metabolism. Drug Metab Pharmacokinet 17:167-189.
79. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, and Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 125:803-808.
80. Nebert DW (1989) The Ah locus: genetic differences in toxicity, cancer, mutation and birth defects. Crit Rev Toxicol 20:153-157.
81. Numayama-Tsuruta K, Kobayashi A, Sogawa K, and Fujii-Kuriyama Y (1997) A point mutation responsible for defective function of the aryl-hydrocarbon- receptor nuclear translocator in mutant Hepa-1c1c7 cells. Eur J Biochem 246:486-495.
82. Okey AB, Manchester DK, Feeley MM, Grant DL, and Gilman A (1995) Ah receptor characterization in human placenta samples. Organohalogen Compd 25:177-184.
83. Okey AB, Vella LM, and Harper PA (1989) Detection and characterization of a low affinity form of cytosolic Ah receptor in livers of mice nonresponsive to induction of cytochrome P1-450 by 3-methylcholanthrene. Mol Pharmacol 35:823-830.
84. Okino ST and Whitlock JP Jr (2000) The aromatic hydrocarbon receptor, transcription and endocrine aspects of dioxin action. Vitam Horm 59:241-264.
85. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, and Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388.
86. Pantuck EJ, Pantuck CB, Garland WA, Min BH, Wattenberg LW, Anderson KE, Kappas A, and Conney AH (1979) Stimulatory effect of Brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 25:88-95.
87. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, and Vilarem MJ (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268:6346-6357.
88. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, and Vilarem MJ (2000) Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 274:707-713.
89. Pauli-Magnus C, Rekersbrink S, Klotz U, and Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364:551-557.
90. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, and Falloon J (2000) Indinavir concentrations and St John's wort. Lancet 355:547-548.
91. Postlind H, Vu TP, Tukey RH, and Quattrochi LC (1993) Response of human CYP1-luciferase plasmids to 2,3,7,8-tetrachlorodibenzo-p-dioxin and polycyclic aromatic hydrocarbons. Toxicol Appl Pharmacol 118:255-262.
92. Riley RJ (2001) The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Discovery Dev 4:45-54.
93. Rost KL, Brosicke H, Brockmoller J, Scheffler M, Helge H, and Roots I (1992) Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 52:170-180.
94. Rost KL, Brosicke H, Heinemeyer G, and Roots I (1994) Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 20:1204-1212.
95. Sachse C, Brockmoller J, Bauer S, and Roots I (1999) Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449.
96. Salem SA, Rajjayabun P, Shepherd AM, and Stevenson IH (1978) Reduced induction of drug metabolism in the elderly. Age Ageing 7:68-73.
97. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, and Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56.
98. Savkur RS, Wu Y, Bramlett KS, Wang M, Yao S, Perkins D, Totten M, Searfoss G 3rd, Ryan TP, Su EW, et al. (2003) Alternative splicing within the ligand binding domain of the human constitutive androstane receptor. Mol Genet Metab 80:216-226.
99. Scheel J, Hussong R, Schrenk D, and Schmitz HJ (2002) Variability of the human aryl hydrocarbon receptor nuclear translocator (ARNT) gene. J Hum Genet 47:217-224.
100. Schmucker DL (2001) Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 18:837-851.
101. Schuetz EG (2004) Lessons from the CYP3A4 promoter. Mol Pharmacol 65:279-281.
102. Schuetz EG, Furuya KN, and Schuetz JD (1995) Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmcol Exp Ther 275:1011-1018.
103. Schuetz EG, Schinkel AH, Relling MV, and Schuetz JD (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001-4005.
104. Seeff LB, Cuccrevini BA, Zimmerman HJ, Adler E. and Benjamin SB (1986) Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med 104:399-404.
105. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variation in human liver microsome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
106. Smart J and Daly AK (2000) Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 10:11-24.
107. Smith CW, Patton JG, and Nadal-Ginard B (1989) Alternative splicing in the control of gene expression. Annu Rev Genet 23:527-577.
108. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, and Ishizaki T (1992) Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 262:1195-1202.
109. Squires EJ, Sueyoshi T, and Negishi M (2004) Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J Biol Chem 279:49307-49314.
110. Sueyoshi T and Negishi M (2001) Phenobarbital response elements of cytochrome p450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 41:123-143.
111. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, et al. (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137-1143.
112. Tirona RG, Leake BF, Merino G, and Kim RB (2001) Polymorphism in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669-35675.
113. Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003a) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228.
114. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, et al. (2003b) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220-224.
115. Tomita S, Jiang HB, Ueno T, Takagi S, Tohi K, Maekawa S, Miyatake A, Furukawa A, Gonzalez FJ, Takeda J, et al. (2003) T cell-specific disruption of arylhydrocarbon receptor nuclear translocator (Arnt) gene causes resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced thymic involution. J Immunol 171:4113-4120.
116. Twum-Barima Y, Finnigan T, Habash AI, Cape RD, and Carruthers SG (1984) Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol 17:595-597.
117. Villikka K, Kivisto KT, Backman JT, Olkkola KT, and Neuvonen PJ (1997) Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 61:8-14.
118. Watanabe T, Imoto I, Kosugi Y, Fukuda Y, Mimura J, Fujii Y, Isaka K, Takayama M, Sato A, and Inazawa J (2001) Human arylhydrocarbon receptor repressor (AHRR) gene: genomic structure and analysis of polymorphism in endometriosis. J Hum Genet 46:342-346.
119. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, and Guzelian PS (1989) Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Investig 83:688-697.
120. Waxman DJ (1999) P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR and PPAR. Arch Biochem Biophys 369:11-23.
121. Wentworth JM, Agostini M, Love J, Schwabe JW, and Chatterjee VK (2000) St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 166:R11-R16.
122. Westlind A, Lofberg L, Tindberg N, Andersson TB, and Ingelman-Sundberg M (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201-205.
123. Whitlock JP Jr (1999) Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 9:103-125.
124. Wojnowski L (2004) Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26:192-199.
125. Woodahl EL and Ho RJ (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 51:11-19.
126. Wyde ME, Bartolucci E, Ueda A, Zhang H, Yan B, Negishi M, and You L (2003) The environmental pollutant 1,1-dichloro-2,2-bis (p-chlorophenyl)ethylene induces rat hepatic cytochrome P450 2B and 3A expression through the constitutive androstane receptor and pregnane X receptor. Mol Pharmacol 64:474-481.
127. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo K, and Sugimachi K (2002) Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74:571-572.
128. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, et al. (2001) The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555-572.
129. Zhou HH (2001) CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. Clin Chim Acta 313:203-208.
130. Zhou HH, Anthony LB, Wood AJ, and Wilkinson GR (1990) Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 30:471-475.